InvestorsHub Logo
Followers 116
Posts 1878
Boards Moderated 0
Alias Born 11/22/2017

Re: sentiment_stocks post# 224962

Wednesday, 05/01/2019 7:48:23 PM

Wednesday, May 01, 2019 7:48:23 PM

Post# of 704516

In reviewing the Phase III GBM Trial, Dr. Bosch’s presentation also took note of encouraging projections by independent analysts in regard to the median overall survival (OS) and median progression free survival (PFS) based on the trial metrics reported by the Company during ASCO.


https://nwbio.com/dcvax-clinical-program-updates-presented-dr-marnix-bosch-boston-scientific-conference/

Sentiment,

Can you explain to me why Northwest Biotherapeutics is telling us in a PR that they took note of encouraging projections by independent analysts in regard to median progression free survival based on the trial metrics reported by the Compagny during ASCO 2017 IF the hold on recruitment (Aug.2015) was caused by pseudo-progression in the treatment arm?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News